Rituxan rituximab regulatory update

BIIB and DNA submitted an sBLA for use of Rituxan as first-line treatment of previously-untreated patients with low-grade or follicular, CD20-positive, B cell non-Hodgkin's lymphoma (NHL) in combinati...